Business Wire (Free subscription) | 11/12/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its collaboration with Roche received the award for ‘Best Partnership
Business Wire (Free subscription) | yesterday
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 27th Annual J.P. Morgan
PR News Wire (Free subscription) | 01/12/2008
CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ) announces the following webcast: What: New findings published in the journal Nature on the role of a microRNA, known as miR-21, in heart failure When: Monday, December 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT Where: How: Live on the Internet. Simply log onto our website listed above. If you are unable to...
The Earth Times Online Newspaper (Free subscription) | 30/11/2008
CAMBRIDGE, Mass. & CARLSBAD, Calif. - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication o
Business Wire (Free subscription) | 30/11/2008
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover,
Medical News Today (Free subscription) | 31/12/2008
Alnylam Pharmaceuticals, Inc.
Market Wire (Free subscription) | 23/12/2008
VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that one of the company's collaborators, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) seeking approval to begin a human clinical trial for a product candidate utilizing Tekmira's...
Xconomy (Free subscription) | 23/12/2008
Alnylam Pharmaceuticals, one of the leaders in developing drugs through RNA interference, has achieved another big first for the emerging field. The Cambridge, MA-based drug developer (NASDAQ: ALNY) is announcing today that it has filed an application with the FDA to start the first clinical trial of an RNAi drug that can circulate throughout the [...]
Business Wire (Free subscription) | 23/12/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has submitted an investigational new drug (IND) application to the U.S. Food
Business Wire (Free subscription) | 19/12/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has published data in the journal Oligonucleotides demonstrating robust
The Street (Free subscription) | 18/12/2008
... have that printed on T-shirts Anyway, here is my clinical trials list. I hope you find it useful. Alnylam Pharmaceuticals is conducting a phase II study of its lead RNA interference (RNAi) drug ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus with results to be released in mid-2009. Amgen is expanding its experimental long-acting osteoporosis denosumab...
Fool.com (Free subscription) | 17/12/2008
... run the risk of losing more money if the drugs turn out to be duds. Glaxo has similar deals with Alnylam Pharmaceuticals' (Nasdaq: ) and Isis Pharmaceuticals' (Nasdaq: ) joint venture , among .By not buying the company outright, Glaxo also keeps the fire under Dynavax. Sometimes small biotech companies are successful not because they're smarter than their pharmaceutical counterparts, but...
PR News Wire (Free subscription) | 15/12/2008
ARCH Venture Partners focuses on creating early-stage technology companies in the life, physical and information sciences, which emanate from universities, national laboratories and corporate research labs. With $1.5 billion under management, ARCH has invested in the earliest rounds of more than 135 companies over a 22-year history. Early-stage biotechnology investments include Illumina, Ikaria, ...
Medical News Today (Free subscription) | 11/12/2008
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has formed an exclusive collaboration with the University of California, San Francisco (UCSF) to evaluate the potential of an RNAi therapeutic targeting a heterotrimeric G protein alpha-subunit, known as G-alpha q or GNAQ, for the treatment of metastatic uveal melanoma.
Business Wire (Free subscription) | 10/12/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has formed an exclusive collaboration with the University of California, San
